RECRUITING

Intraoperative Tumor Margin Identification With ICG Dye Imaging

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

In this research study we want to learn more about the use of indocyanine green (ICG) during bone or soft tissue mass resections. Indocyanine green (ICG) is a type of dye that is used in medical diagnostics. We want to determine if ICG-guided tumor resection is more effective in obtaining negative margins. Lastly, we want to assess traditional oncologic outcomes of local recurrence, time to metastatic disease, and overall and disease specific survival.

Official Title

Evaluation of Intraoperative Tumor Margin Identification With Fluorescent Dye Imaging

Quick Facts

Study Start:2022-05-25
Study Completion:2025-10-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04752137

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * All patients 18 years of age or older who present to Massachusetts General Hospital Department of Orthopaedic Surgery with a benign or malignant bone or soft tissue mass that is consented for surgery during the study period.
  1. * Pregnant or nursing patients
  2. * Patients with previously known anaphylaxis to IV contrast or iodine (other allergies may be considered on a case-by-case basis)
  3. * Patients in renal failure who are not cleared for ICG administration by their primary physician or oncologist

Contacts and Locations

Study Contact

Santiago A Lozano-Calderon, MD, PhD
CONTACT
(617) 643-4947
SLOZANOCALDERON@mgh.harvard.edu
Lucy Hederick, BA
CONTACT
(617) 726-4932
lhederick@mgh.harvard.edu

Principal Investigator

Santiago A Lozano-Calderon, MD, PhD
PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital

Study Locations (Sites)

Massachusetts General Hospital
Boston, Massachusetts, 02114
United States

Collaborators and Investigators

Sponsor: Massachusetts General Hospital

  • Santiago A Lozano-Calderon, MD, PhD, PRINCIPAL_INVESTIGATOR, Massachusetts General Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-05-25
Study Completion Date2025-10-01

Study Record Updates

Study Start Date2022-05-25
Study Completion Date2025-10-01

Terms related to this study

Additional Relevant MeSH Terms

  • Benign Neoplasm
  • Malignant Neoplasm